Patents Issued in August 30, 2016
  • Patent number: 9428512
    Abstract: The present invention relates to compounds of formula (I) and salts thereof: wherein R1 is n-C3-6alkyl; R2 is hydrogen or methyl; R3 is hydrogen or C1-6alkyl, and m is an integer having a value of 1 to 4; are inducers of human interferon. Compounds which induce human interferon may be useful in the treatment of various disorders, for example the treatment of allergic diseases and other inflammatory conditions, for example allergic rhinitis and asthma, infectious diseases and cancer, and may also be useful as vaccine adjuvants.
    Type: Grant
    Filed: November 18, 2013
    Date of Patent: August 30, 2016
    Assignee: GLAXOSMITHKLINE LLC
    Inventors: Diane Mary Coe, Stephen Allan Smith
  • Patent number: 9428513
    Abstract: The present invention encompasses compounds of general formula (I) wherein the groups R1 to R3, X3 to X6 have the meanings given in the claims and in the specification. The compounds of the invention are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation pharmaceutical preparations containing such compounds and their uses as a medicament.
    Type: Grant
    Filed: November 4, 2014
    Date of Patent: August 30, 2016
    Assignee: Boehringer Ingelheim International GmbH
    Inventor: Harald Engelhardt
  • Patent number: 9428514
    Abstract: The present invention provides for compounds of formula (I) wherein Y1, Y2, R1, R2, R3, A1, A2, A3, and A4, have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents for the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).
    Type: Grant
    Filed: December 9, 2014
    Date of Patent: August 30, 2016
    Assignee: AbbVie Inc.
    Inventors: Andrew Bogdan, Warren M. Kati, Keith F. McDaniel, Chang H. Park, George S. Sheppard, Le Wang
  • Patent number: 9428515
    Abstract: The present invention encompasses compounds of the general formula I wherein the groups A, R1 to R2 and X have the meanings given in the claims and in the specification. The compounds of the invention are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation pharmaceutical preparations containing such compounds and their uses as a medicament.
    Type: Grant
    Filed: May 7, 2015
    Date of Patent: August 30, 2016
    Assignee: Boehringer Ingelheim International GmbH
    Inventor: Harald Engelhardt
  • Patent number: 9428516
    Abstract: The present disclosure is directed to crystalline forms of morphine sulfate and pharmaceutical compositions comprising any of the crystalline forms of morphine sulfate. Also provided are processes for the preparation of crystalline forms of morphine sulfate.
    Type: Grant
    Filed: September 29, 2015
    Date of Patent: August 30, 2016
    Assignee: Johnson Matthey Public Limited Company
    Inventors: Nicholas D. Paschalides, Mahmoud Mirmehrabi
  • Patent number: 9428517
    Abstract: Compounds of the formula II: wherein R1 and R2 are independently H, F or CH3; or R1 forms an ethynyl bond and R2 is H or C3-C6 cycloalkyl which is optionally substituted with one or two substituents independently selected from methyl, CF3, OMe or halo; R3 is C1-C3 alkyl or C3-C6 cycloalkyl, either of which is optionally substituted with one or two methyl and/or a fluoro, trifluoromethyl or methoxy, when R3 is C3-C6 cycloalkyl it may alternatively be gem substituted with fluoro; R4 is methyl or fluoro; m is 0, 1 or 2; E is a bond, or thiazolyl, optionally substituted with methyl or fluoro; A1 is CH or N, A2 is CR6R7 or NR6, provided at least one of A1 and A2 comprises N; R6 is H, C1-C4 alkyl, C1-C4 haloalkyl, C1-C3 alkyl-O—C1-C3 alkyl, or when A2 is C, R6 can also be C1-C4 alkoxy or F; R7 is H, C1-C4 alkyl or F or a pharmaceutically acceptable salt, N-oxide or hydrate thereof, have utility in the treatment of disorders characterized by inappropriate expression or activation of cathepsin K, such as oste
    Type: Grant
    Filed: November 13, 2015
    Date of Patent: August 30, 2016
    Assignee: MEDIVIR AB
    Inventors: Lourdes Salvador Oden, Magnus Nilsson, Pia Kahnberg, Bertil Samuelsson, Urszula Grabowska
  • Patent number: 9428518
    Abstract: A sensitizer in a dye-sensitized solar cell, including a compound of formula (I?) where: R1 and R2 are hydrogen, a halogen, an alkyl group, a cycloalkyl group, an aryl group, a hetaryl group, an alkoxy group, an aryloxy group, an arylthio group, a hetaryloxy group, a hetarylthio group, a diarylamino group, or a dialkylamino group; m, n are each independently an integer from 0-4; X is sulfur, oxygen, or NR3, where R3 is hydrogen, an alkyl group, a cycloalkyl group, an aryl group, or a hetaryl group; Y1 is oxygen or N—Z-A, where A is —COOM, —SO3M, or —PO3M, where M is hydrogen, an alkali metal cation, or [NR?]4+, where each R? is independently hydrogen or an alkyl group, and where Z is C1-C6-alkylene or 1,4-phenylene, where the phenylene radical is optionally substituted by one or more alkyl, nitro, cyano, and halogen substituents.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: August 30, 2016
    Assignees: BASF SE, Max-Planck-Gesellschaft zur Foerderung der Wissenschaften e.V.
    Inventors: Henrike Wonneberger, Neil Gregory Pschirer, Flavio Luiz Benedito, Ingmar Bruder, Robert Send, Yulian Zagranyarski, Chen Li, Klaus Muellen, Long Chen, Artem Nikolaevich Skabeev
  • Patent number: 9428519
    Abstract: The present invention belongs to the field of natural medicine and pharmaceutical chemistry, and relates to novel homoharringtonine acylated derivatives of formula (I) and formula (II) and a pharmaceutically acceptable salt thereof, to a process for the preparation of these compounds, compositions containing such compounds and their use in preparing antineoplastic medicaments.
    Type: Grant
    Filed: August 20, 2012
    Date of Patent: August 30, 2016
    Assignee: HANGZHOU BENSHENG PHARMACEUTICAL CO., LTD.
    Inventors: Rongzhen Xu, Frank Rong, Fuwen Xie, Hongxi Lai
  • Patent number: 9428520
    Abstract: The present invention relates to a pharmaceutical composition for the prevention or treatment of atopy comprising the extract of Daphne genkwa, the fraction thereof, of the compound isolated from the same as an active ingredient. More precisely, the extract of Daphne genkwa, the fraction thereof, or the compound isolated from the same, genekwadapnin or yuanhuacine, of the present invention can increase the secretion of cytokine in Th1 immune cells and suppress atopy in the atopy mouse model, so that the extract of Daphne genkwa, the fraction thereof, or the compound isolated from the same of the present invention can be effectively used for the prevention or treatment of atopy.
    Type: Grant
    Filed: May 17, 2012
    Date of Patent: August 30, 2016
    Assignee: KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY
    Inventors: Jae Wha Kim, Kyung Seop Ahn, Ho Bum Kang, Sei Ryang Oh, Jae Jong Go, Joo Heon Kim, Jang Mi Sun, Jae Sung Song, Hyun Woo Oh, Da Jung Ji
  • Patent number: 9428521
    Abstract: A process for the production of a carbodiimide, comprising the steps of: (1) reacting an amine represented by the following formula (A) with carbon disulfide in the presence of a catalyst at a reaction temperature of 50 to 150° C. to obtain a thiourea represented by the following formula (B): (In the above formula (A), R is a hydrogen atom or an alkyl group having 1 to 6 carbon atoms.) (In the above formula (B), R is as defined in the above formula (A); (2) desulfurizing the obtained thiourea with a hypochlorite in the presence of a basic compound to obtain a carbodiimide represented by the following formula (C): (In the above formula (C), R is as defined in the above formula (A)); and (3) purifying the obtained carbodiimide.
    Type: Grant
    Filed: June 15, 2011
    Date of Patent: August 30, 2016
    Assignees: KAWAGUCHI CHEMICAL INDUSTRY CO., LTD., TEIJIN LIMITED
    Inventors: Kenji Suzuki, Tsukasa Kato, Tsutomu Yamada, Yuya Kamada, Shinichiro Shoji
  • Patent number: 9428522
    Abstract: Disclosed are novel piperazine derivatives that act as agonists of the ?7 nAChR. Also disclosed are pharmaceutical compositions, methods of treating inflammatory conditions, methods of treating CNS disorders, methods for inhibiting cytokine release from mammalian cells and methods for the preparation of the novel compounds.
    Type: Grant
    Filed: July 29, 2014
    Date of Patent: August 30, 2016
    Assignee: The Feinstein Institute for Medical Research
    Inventors: Roger B. Clark, Daniel Elbaum
  • Patent number: 9428523
    Abstract: The present invention is directed to compounds, tautomers and pharmaceutically acceptable salts of the compounds which are disclosed, wherein the compounds have the structure of Formula I, and the variable R1 is as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
    Type: Grant
    Filed: February 9, 2016
    Date of Patent: August 30, 2016
    Assignee: Pfizer Inc.
    Inventors: Michael Aaron Brodney, Elizabeth Mary Beck, Christopher Ryan Butler, Lei Zhang, Brian Thomas O'Neill, Gabriela Barreiro, Erik Alphie LaChapelle, Bruce Nelsen Rogers
  • Patent number: 9428524
    Abstract: This invention relates to compounds of formula II: wherein R1, R2, ProtSH, and ProtNH are as defined, to processes for the synthesis of ecteinascidins of formula I from compounds of formula II, and to processes for the synthesis of compounds of formula II.
    Type: Grant
    Filed: May 24, 2011
    Date of Patent: August 30, 2016
    Assignee: PHARMA MAR, S.A.
    Inventors: Ma Jesús Martin López, Andrés Francesch Solloso, Maria del Carmen Cuevas Marchante
  • Patent number: 9428525
    Abstract: A composition including a porous metal organic framework (MOF) including an open metal site and a guest species capable of charge transfer that can coordinate with the open metal site, wherein the composition is electrically conductive. A method including infiltrating a porous metal organic framework (MOF) including an open metal site with a guest species that is capable of charge transfer; and coordinating the guest species to the open metal site to form a composition including an electrical conductivity greater than an electrical conductivity of the MOF.
    Type: Grant
    Filed: April 18, 2016
    Date of Patent: August 30, 2016
    Assignee: Sandia Corporation
    Inventors: Albert Alec Talin, Mark D. Allendorf, Vitalie Stavila, Francois Leonard
  • Patent number: 9428527
    Abstract: A symmetric hyperbranched type silicone-modified polymerizable compound contains a compound represented by the following general formula (1). A hyperbranched type silicone-modified polymerizable compound has flexibility at the branched skeleton itself than the conventional ones, and reactivity of a polymerizable functional group is good and it is positionally and sterically symmetric, while it has a highly branched structure having siloxane chains.
    Type: Grant
    Filed: January 31, 2014
    Date of Patent: August 30, 2016
    Assignee: SHIN-ETSU CHEMICAL CO., LTD.
    Inventor: Hatsuhiko Hattori
  • Patent number: 9428528
    Abstract: The present invention provides novel phenicol derivatives, their use for the treatment of infections in mammals, pharmaceutical composition containing these novel compounds, and methods for the preparation of these compounds.
    Type: Grant
    Filed: March 16, 2016
    Date of Patent: August 30, 2016
    Assignee: Zoetis Services LLC
    Inventors: Michael Curtis, Richard A Ewin, Timothy Allan Johnson, Susan M. K. Sheehan
  • Patent number: 9428529
    Abstract: The present invention provides processes for purifying a trivalent phosphorous ligand that can be used for the preparation of catalysts for a hydroformylation process. In one embodiment, a process comprises: (A) contacting a trivalent phosphorous ligand, a contaminant metal, a first solvent, a polar complexing agent and a second solvent to form a mixture, (B) obtaining a first phase comprising the ligand and the first solvent, (C) obtaining a second phase comprising the second solvent and at least one complex of the contaminant metal and the polar complexing agent, and (D) separating the two phases prior to preparing a catalyst for use in a hydroformylation reactor.
    Type: Grant
    Filed: September 7, 2012
    Date of Patent: August 30, 2016
    Assignee: Dow Technology Investments LLC
    Inventor: Glenn A. Miller
  • Patent number: 9428530
    Abstract: The present invention relates to novel derivatives of oxazaphosphorines that are pre-activated, to the methods for preparing same, to the pharmaceutical compositions containing same and to the therapeutic use thereof, in particular for treating cancer.
    Type: Grant
    Filed: July 2, 2015
    Date of Patent: August 30, 2016
    Assignee: INSTITUT GUSTAVE ROUSSY
    Inventors: Angelo Paci, Thierry Martens, Michael Rivard, Patrick Couvreur, Didier Desmaele, Joachim Caron
  • Patent number: 9428531
    Abstract: The invention describes a novel type of nickel-based complex and its preparation method. The invention also concerns the use of said complex in a process for the transformation of olefins.
    Type: Grant
    Filed: April 28, 2015
    Date of Patent: August 30, 2016
    Assignees: IFP Energies nouvelles, Universiteit Van Amsterdam
    Inventors: Pierre Boulens, Pierre-Alain Breuil, Joost Reek, Helene Olivier-Bourbigou
  • Patent number: 9428532
    Abstract: Sugar-acrylic monomers are synthesized to have a carbohydrate moiety linked to an acrylate group. The sugar-acrylic monomers may be polymerized to form polymers, adhesives, hydrogels, and the like. The sugar-acrylic monomers and polymers may be used in tissue engineering, adhesives and sealers, wound healing, and the like.
    Type: Grant
    Filed: September 26, 2014
    Date of Patent: August 30, 2016
    Assignee: Empire Technology Development LLC
    Inventors: William B. Carlson, Gregory D. Phelan, Phillip A. Sullivan
  • Patent number: 9428533
    Abstract: The present invention provides compounds of the formula, wherein A, B, G, R2, R6, and X are defined herein, pharmaceutical compositions of the same, and methods for treating or inhibiting development of AGE- and/or ALE-associated complications in subjects in need thereof.
    Type: Grant
    Filed: February 20, 2014
    Date of Patent: August 30, 2016
    Assignee: Nephrogenex, Inc
    Inventors: Raja G. Khalifah, Roger E. Marti
  • Patent number: 9428534
    Abstract: A novel class of pharmaceuticals which comprises a Locked Nucleic Acid (LNA) which can be used in antisense therapy. These novel oligonucleotides have improved antisense properties. The novel oligonucleotides are composed of at least one LNA selected from beta-D-thio/amino-LNA or alpha-L-oxy/thio/amino-LNA. The oligonucleotides comprising LNA may also include DNA and/or RNA nucleotides.
    Type: Grant
    Filed: March 12, 2013
    Date of Patent: August 30, 2016
    Assignee: Roche Innovation Center Copenhagen A/S
    Inventors: Signe M. Christensen, Nikolaj Dam Mikkelsen, Miriam Frieden, Henrik Frydenlund Hansen, Troels Koch, Daniel Sejer Pedersen, Christoph Rosenbohm, Charlotte Albaek Thrue, Majken Westergaard
  • Patent number: 9428535
    Abstract: The present disclosure provides methods of increasing the level of a polypeptide of interest in a mammalian subject by administering a polynucleotide having one or more chemical modifications and a Protein:Cytokine ratio of greater than 100.
    Type: Grant
    Filed: October 3, 2012
    Date of Patent: August 30, 2016
    Assignee: Moderna Therapeutics, Inc.
    Inventors: Antonin de Fougerolles, Atanu Roy, Jason P. Schrum, Suhaib Siddiqi, Paul Hatala, Stephane Bancel
  • Patent number: 9428536
    Abstract: Compositions and methods relating to immunostimulatory RNA oligomers are provided. The immunostimulatory RNA molecules are believed to represent natural ligands of one or more Toll-like receptors, including Toll-like receptor 7 (TLR7) and Toll-like receptor 8 (TLR8). The compositions and methods are useful for stimulating immune activation. Methods useful for screening candidate immunostimulatory compounds are also provided.
    Type: Grant
    Filed: January 21, 2014
    Date of Patent: August 30, 2016
    Assignee: Zoetis Belgium SA
    Inventors: Grayson B. Lipford, Stefan Bauer, Hermann Wagner
  • Patent number: 9428537
    Abstract: The present invention features compositions and methods relating to tRNA-derived small RNAs (tsRNAs). Provided herein are oligonucleotide compositions that are complementary to tsRNAs, in particular leuCAGtsRNA, and methods of using the oligonucleotides for the regulation of respective tsRNA. Further provided are methods of inducing apoptosis through the inhibition of leuCAGtsRNA.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: August 30, 2016
    Assignee: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
    Inventors: Mark A. Kay, Hak kyun Kim, Shengchun Wang
  • Patent number: 9428538
    Abstract: The present invention relates to an optimized in vivo delivery system with endosomolytic agents for nucleic acid of therapeutic interest conjugated to molecules facilitating endocytosis, in particular for use in the treatment of cancer.
    Type: Grant
    Filed: October 27, 2015
    Date of Patent: August 30, 2016
    Assignees: DNA THERAPEUTICS, INSTITUT CURIE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Jian-Sheng Sun, Marie Dutreix, Maria Quanz
  • Patent number: 9428539
    Abstract: The present invention discloses compound 2?,3?,5?-trihydroxy-androst-6-one, having the structure of formula (I). The present invention also discloses a plurality of methods for preparing the compound and a use of the compound.
    Type: Grant
    Filed: March 28, 2014
    Date of Patent: August 30, 2016
    Assignee: Guangzhou Cellprotek Pharmaceutical Co., Ltd.
    Inventors: Jingxia Zhang, Suizhen Lin, Minyu Xie
  • Patent number: 9428540
    Abstract: The present invention relates to certain unsaturated fatty acid derivatives of therapeutically active glucocorticoides-fatty acid esters of glucocorticoids as anti-inflammatory and anti-cancer agents and pharmaceutical formulations containing them.
    Type: Grant
    Filed: March 13, 2008
    Date of Patent: August 30, 2016
    Assignee: CLAVIS PHARMA ASA
    Inventors: Finn Myhren, Marit Liland Sandvold, Ole Henrik Eriksen, Steinar Hagen
  • Patent number: 9428541
    Abstract: The present invention provides a compound which is an inhibitor of sphingolipid biosynthesis for use in the treatment of a disease which has a secondary Niemann-Pick type C disease like cellular phenotype.
    Type: Grant
    Filed: September 13, 2013
    Date of Patent: August 30, 2016
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, The Chancellor, Masters, and Scholars of the University of Oxford
    Inventors: Frances Mary Platt, Emyr Lloyd-Evans, Forbes Dennison Porter
  • Patent number: 9428542
    Abstract: The present invention relates to a lupane triterpenoid derivatives and pharmaceutical use thereof, specifically relates to a lupane triterpenoid derivatives of formula (I)˜(III), a pharmaceutical composition and a combination preparation comprising a lupane triterpenoid derivatives or a pharmaceutically acceptable salt thereof in a therapeutically-effective dose, particularly relates to the use in preparation of a medicament for the treatment of HIV-1/AIDS.
    Type: Grant
    Filed: January 30, 2013
    Date of Patent: August 30, 2016
    Assignees: JIANGXI QINGFENG PHARMACEUTICAL INC.
    Inventor: Feng Lu
  • Patent number: 9428543
    Abstract: The invention provides a one-step process for preparing a cell-binding agent cytotoxic agent conjugate comprising contacting a cell-binding agent with a cytotoxic agent to form a first mixture comprising the cell-binding agent and the cytotoxic agent and contacting the first mixture comprising the cell-binding agent and the cytotoxic agent with a bifunctional crosslinking reagent, which provides a linker, in a solution having a pH of about 4 to about 9 to provide a second mixture comprising the cell-binding agent cytotoxic agent conjugate, wherein the cell-binding agent is chemically coupled through the linker to the cytotoxic agent, free cytotoxic agent, and reaction by-products. The second mixture is then optionally subjected to purification to provide a purified cell-binding agent cytotoxic agent conjugate.
    Type: Grant
    Filed: June 24, 2014
    Date of Patent: August 30, 2016
    Assignee: ImmunoGen, Inc.
    Inventors: Xinfang Li, Jared M. Worful
  • Patent number: 9428544
    Abstract: It is an object of the present invention to provide a method for eluting an adsorbed protein that suppresses a decrease in protein adsorption ability, in a method for purifying a protein using a protein-adsorbing porous membrane. The present invention provides a method for purifying a protein, comprising an adsorption step and an elution step, wherein in the elution step, at least one eluent is passed in the opposite direction with respect to the direction of the passage of a stock solution containing an adsorption target protein, in the adsorption step.
    Type: Grant
    Filed: September 28, 2012
    Date of Patent: August 30, 2016
    Assignee: ASAHI KASEI CHEMICALS CORPORATION
    Inventors: Yuta Sato, Naoyuki Shinohara, Hironobu Shirataki
  • Patent number: 9428545
    Abstract: The present invention provides a process for the isolation of one or more proteins from a protein solution. This process comprising the steps of: a) providing a protein solution comprising one or more specific proteins and having a preset pH and a preset ionic strength or conductivity, b) applying the protein solution to a packed bed or expanded bed column comprising an adsorbent, and c) obtaining one or more proteins) from the column; wherein the protein solution has been not supplemented with an alcohol.
    Type: Grant
    Filed: April 16, 2015
    Date of Patent: August 30, 2016
    Assignee: Therapure Biopharma Inc.
    Inventor: Allan Otto Fog Lihme
  • Patent number: 9428546
    Abstract: The present disclosure provides methods for purifying products from a fluid. In some embodiments, provided purification methods use a combination of purification modes (e.g., protein A and ion exchange) operated in tandem, wherein at least one of the modes utilizes weak partitioning. In some embodiments, provided purification methods operate under robust conditions in which a degree of binding between a product and resin is maintained despite variations in operating parameters.
    Type: Grant
    Filed: July 29, 2011
    Date of Patent: August 30, 2016
    Assignee: Pfizer Inc.
    Inventors: Jonathan Lee Coffman, Ranganathan Godavarti, Michael Shamashkin
  • Patent number: 9428547
    Abstract: The invention generally relates to compositions that include sets of magnetic particles, members of each set being conjugated to an antibody specific for a pathogen.
    Type: Grant
    Filed: April 21, 2011
    Date of Patent: August 30, 2016
    Assignee: DNA Electronics, Inc.
    Inventors: Sergey A. Dryga, Victor C. Esch, Lisa-Jo Ann Clarizia, Eddie W. Adams, Thearith H. Ung, Ravil A. Sitdikov
  • Patent number: 9428548
    Abstract: The present invention provides methods for purifying a polypeptide comprising a CH2/CH3 region, comprising binding the polypeptide to Protein A and eluting with a pH gradient starting at a low pH.
    Type: Grant
    Filed: September 1, 2010
    Date of Patent: August 30, 2016
    Assignee: Genentech, Inc.
    Inventors: Arick Brown, Christopher J. Dowd, Asha Nandini Radhamohan
  • Patent number: 9428549
    Abstract: The present invention relates to derivatives of N-urea substituted amino acids, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the N-formyl peptide 2 receptor.
    Type: Grant
    Filed: July 10, 2014
    Date of Patent: August 30, 2016
    Assignee: Allegran, Inc.
    Inventors: Richard L. Beard, Tien T. Duong, John E. Donello, Veena Viswanath, Michael E. Garst
  • Patent number: 9428550
    Abstract: The present disclosure relates to methods and uses of C-terminal peptides for inhibiting neuronal cell death or dysfunction, such as retinal ganglion cell death or dysfunction, treating retinal degenerative disorders, stroke, CNS and PNS insults. The disclosure also relates to the C-terminal peptides, fusion proteins and compositions thereof.
    Type: Grant
    Filed: January 16, 2013
    Date of Patent: August 30, 2016
    Assignee: Governing Council of the University of Toronto
    Inventor: Paulo Koeberle
  • Patent number: 9428551
    Abstract: The present invention provides novel therapeutic antimicrobial peptides that are bactericides and have an inhibitory effect on biofilms produced by biofilm-forming bacteria and especially biofilm-forming Staphyloccocal bacteria. The invention includes the nucleic acids encoding the polypeptides, methods of treating bacterial infections, medical devices or implants or prosthetics impregnated with, covered or coated in the polypeptides, and means of delivery of the peptide to the oral cavity.
    Type: Grant
    Filed: May 15, 2014
    Date of Patent: August 30, 2016
    Assignee: The University of Manchester
    Inventors: Mathew Upton, Stephanie Sandiford
  • Patent number: 9428552
    Abstract: Stem cells are mobilized from bone marrow by administering an amount of Phe-Pro-His-Phe-Asp-Leu-Ser-His-Gly-Ser-Ala-Gln-Val-Ser-Asp-Lys-Pro (SEQ ID NO: 2) or Phe-Ala-His-Phe-Asp-Leu-Ser-His-Gly-Ser-Ala-Gln-Val-Ser-Asp-Lys-Pro (SEQ ID NO: 3) effective to mobilize the stem cells. This is useful for promoting bodily tissue regeneration in a patient in need of tissue regeneration treatment. Alternatively, the mobilized stem cells can be collected for transplant.
    Type: Grant
    Filed: November 18, 2013
    Date of Patent: August 30, 2016
    Assignee: Wellstat Therapeutics Corporation
    Inventors: Irena Tsyrlova, Fawn Petty, Reid W. von Borstel, Julian Reading, Jiong Pei, Joel Saydoff
  • Patent number: 9428553
    Abstract: Antibodies and meditopes that bind to the antibodies are provided, as well as complexes, compositions and combinations containing the meditopes and antibodies, and methods of producing, using, testing, and screening the same, including therapeutic and diagnostic methods and uses.
    Type: Grant
    Filed: February 11, 2013
    Date of Patent: August 30, 2016
    Assignee: City of Hope
    Inventors: John C. Williams, Cindy Zer, Krzysztof Bzymek, Kendra Nicole Avery
  • Patent number: 9428554
    Abstract: The present invention relates to monoclonal antibody specifically binding to polypeptide(s) comprising the amino acid sequence as set forth in SEQ ID No.
    Type: Grant
    Filed: April 30, 2009
    Date of Patent: August 30, 2016
    Assignees: XIAMEN UNIVERSITY, BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.
    Inventors: Ningshao Xia, Jun Zhang, Ying Gu, Shaowei Li, Shengxiang Ge, Zhiqiang He
  • Patent number: 9428555
    Abstract: The invention relates to a truncated L1 protein of the Human Papillomavirus Type 16, a virus-like particle consisting of the protein, a vaccine comprising said virus-like particle, and the use of the vaccine in the prevention of cervical cancer.
    Type: Grant
    Filed: April 29, 2008
    Date of Patent: August 30, 2016
    Assignees: Beijing Wantai Biological Pharmacy Enterprise Co., Ltd., Xiamen University
    Inventors: Ying Gu, Shaowei Li, Minxi Wei, Yangling Xian, Wenxin Luo, Ningshao Xia
  • Patent number: 9428556
    Abstract: Disclosed are yeast-based immunotherapeutic compositions, hepatitis B virus (HBV) antigens, and fusion proteins for the treatment and/or prevention of HBV infection and symptoms thereof, as well as methods of using the yeast-based immunotherapeutic compositions, HBV antigens, and fusion proteins for the prophylactic and/or therapeutic treatment of HBV and/or symptoms thereof.
    Type: Grant
    Filed: January 7, 2015
    Date of Patent: August 30, 2016
    Assignee: GlobeImmune, Inc.
    Inventors: David Apelian, Thomas H. King, Zhimin Guo, Claire Coeshott
  • Patent number: 9428557
    Abstract: Tat protein produced in bulk culture is inactive when induced at conventional optical densities but can be obtained in biologically active form when induced during the logarithmic growth phase.
    Type: Grant
    Filed: February 6, 2009
    Date of Patent: August 30, 2016
    Assignees: ISTITUTO SUPERIORE DI SANITA, UNIVERSITA DEGLI STUDI DI URBINO
    Inventors: Barbara Ensoli, Mauro Magnani
  • Patent number: 9428558
    Abstract: The present invention relates to methods for producing a polypeptide comprising using a signal peptide foreign to the polypeptide, nucleic acid constructs comprising a first and a second nucleotide sequence encoding the signal peptide and the polypeptide and expression vectors and host cells comprising said nucleic acid construct. The signal peptide is the LQ2 peptide which is a hybrid of sequence from the signal peptide of alpha amylase from Bacillus licheniformis and of alpha amylase from Bacillus amyloliquefaciens.
    Type: Grant
    Filed: March 22, 2012
    Date of Patent: August 30, 2016
    Assignee: Novozymes A/S
    Inventors: Steen Troels Joergensen, Anne Breüner
  • Patent number: 9428559
    Abstract: Methods of identifying genes conferring ethanol tolerance in yeasts, genes that confer ethanol tolerance, and mutant strains used to identify such genes are described. A gene herein designated HpETT1 was isolated from the yeast Hansenula polymorpha. Expression of HpETT1 in an ethanol sensitive mutant H. polymorpha strain designated 7E complimented ethanol sensitivity of the mutant. When multiple copies of the HpETT1 were integrated into the genome and overexpressed, the transformed strain demonstrated approximately 10-fold greater resistance to ethanol and resistance to the protein misfolding agent AZC. Expression of HpETT1 also increased ethanol tolerance in Saccharomyces cerevisiae. HpEtt1 has 39% sequence identity to a previously identified protein from S. cerevisiae denoted MPE1, however, the MPE1 gene does not confer ethanol resistance to the 7E mutant.
    Type: Grant
    Filed: January 11, 2013
    Date of Patent: August 30, 2016
    Assignee: Archer Daniels Midland Company
    Inventors: Charles Abbas, Andriy Sibirny, Andriy Voronovsky, Olena Ishchuk
  • Patent number: 9428560
    Abstract: The present invention provides a protein comprising a truncated form of an extracellular region protein of Frizzled 2, which has higher secretion activity than that of a known protein comprising an extralellular cysteine-rich domain of Frizzled 2 in a production cell and bone mass-increasing activity higher than or equal to that of the known protein, or DNA encoding said protein.
    Type: Grant
    Filed: June 21, 2012
    Date of Patent: August 30, 2016
    Assignee: KYOWA HAKKO KIRIN CO., LTD
    Inventors: Makoto Kakitani, Kengo Yamawaki
  • Patent number: 9428561
    Abstract: The present invention provides polypeptide-polymer conjugates. A subject polypeptide-polymer conjugate is useful in a variety of applications, which are also provided.
    Type: Grant
    Filed: March 26, 2009
    Date of Patent: August 30, 2016
    Assignee: The Regents of the University of California
    Inventors: Kevin Edward Healy, Samuel T. Wall, Krishanu Saha, David V. Schaffer
  • Patent number: 9428562
    Abstract: The present invention relates to a medium for the cultivation of eukaryotic cells, the medium comprising as (an) additive(s) DMSO, N-acetylmannosamine (NAcMan), N-acetylglucosamine (NAcGlc), or any combination of two or more of these additives, including the combination of NAcMan and NAcGlc.
    Type: Grant
    Filed: April 2, 2014
    Date of Patent: August 30, 2016
    Assignee: LEK PHARMACEUTICALS D.D.
    Inventor: Tanja Ficko Trcek